{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:42:55Z","timestamp":1792082575744,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05243-7","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T21:43:42Z","timestamp":1737150222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Integrating malaria vaccine and CRISPR\/Cas9 gene drive: a comprehensive strategy for accelerated malaria eradication"],"prefix":"10.1186","volume":"24","author":[{"given":"Israel Charles","family":"Abraham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Ehi","family":"Aboje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventure Michael","family":"Ukoaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehinde","family":"Tom-Ayegunle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Abdulkader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinonyelum Emmanuel","family":"Agbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatosin Ayokunle","family":"Akinruli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiwo Rebecca","family":"Akisanmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel Oyedeji","family":"Oyetola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gbolahan","family":"Olatunji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Kokori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Aderinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"5243_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12936-024-04846-w","volume":"23","author":"N Aderinto","year":"2024","unstructured":"Aderinto N, Olatunji G, Kokori E, Sikirullahi S, Aboje JE, Ojabo RE. A perspective on Oxford\u2019s R21\/Matrix-M\u2122 malaria vaccine and the future of global eradication efforts. Malar J. 2024;23:16.","journal-title":"Malar J"},{"key":"5243_CR2","doi-asserted-by":"crossref","unstructured":"Anwar M. An overview of malaria and Plasmodium. In: Tarique M (ed.). Drug targets for Plasmodium falciparum: historic to future perspectives. Springer, Singapore. 2024.","DOI":"10.1007\/978-981-19-4484-0_1"},{"key":"5243_CR3","doi-asserted-by":"publisher","first-page":"101232","DOI":"10.1016\/j.nmni.2024.101232","volume":"58","author":"G Olatunji","year":"2024","unstructured":"Olatunji G, Kokori E, Kwape JM, Olatunji D, Anthony CS, Ogieuhi IJ, et al. Anopheles stephensi and the impending challenge to malaria eradication in Africa. New Microbes New Infect. 2024;58:101232.","journal-title":"New Microbes New Infect."},{"key":"5243_CR4","unstructured":"WHO. World malaria report 2024. Geneva, World Health Organization, 2024. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024. (Accessed 14 Dec 2024)"},{"key":"5243_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-014719","volume":"9","author":"CB Osoro","year":"2024","unstructured":"Osoro CB, Ochodo E, Kwambai TK, Otieno JA, Were L, Sagam CK, et al. Policy uptake and implementation of the RTS, S\/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation. BMJ Glob Health. 2024;9: e014719.","journal-title":"BMJ Glob Health"},{"key":"5243_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1042\/BST20210281","volume":"50","author":"T Ishizaki","year":"2022","unstructured":"Ishizaki T, Hernandez S, Paoletta MS, Sanderson T, Bushell ESC. CRISPR\/Cas9 and genetic screens in malaria parasites: small genomes, big impact. Biochem Soc Trans. 2022;50:1069\u201379.","journal-title":"Biochem Soc Trans"},{"key":"5243_CR7","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","volume":"18","author":"Y Xu","year":"2020","unstructured":"Xu Y, Li Z. CRISPR-Cas systems: overview, innovations and applications in human disease research and gene therapy. Comput Struct Biotechnol J. 2020;18:2401\u201315.","journal-title":"Comput Struct Biotechnol J"},{"key":"5243_CR8","unstructured":"WHO. Guidance framework for testing of genetically modified mosquitoes. 2nd Edn. Geneva, World Health Organization, 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240025233. (Accessed 15 Dec 2024)"},{"key":"5243_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature14651","volume":"523","author":"S Vinayak","year":"2015","unstructured":"Vinayak S, Pawlowic MC, Sateriale A, Brooks CF, Studstill CJ, Bar-Peled Y, Cipriano MJ, Striepen B. Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum. Nature. 2015;523:477\u201380.","journal-title":"Nature"},{"key":"5243_CR10","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.cell.2016.08.019","volume":"166","author":"SM Sidik","year":"2016","unstructured":"Sidik SM, Huet D, Ganesan SM, Huynh MH, Wang T, Nasamu AS, et al. A genome-wide CRISPR screen in Toxoplasma identifies essential Apicomplexan genes. Cell. 2016;166:1423-1435.e12.","journal-title":"Cell"},{"key":"5243_CR11","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41467-024-44907-x","volume":"15","author":"R D'Amato","year":"2024","unstructured":"D\u2019Amato R, Taxiarchi C, Galardini M, Trusso A, Minuz RL, Grilli S, et al. Anti-CRISPR Anopheles mosquitoes inhibit gene drive spread under challenging behavioural conditions in large cages. Nat Commun. 2024;15:952.","journal-title":"Nat Commun"},{"key":"5243_CR12","doi-asserted-by":"publisher","first-page":"E6736","DOI":"10.1073\/pnas.1521077112","volume":"112","author":"VM Gantz","year":"2015","unstructured":"Gantz VM, Jasinskiene N, Tatarenkova O, Fazekas A, Macias VM, Bier E, et al. Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi. Proc Natl Acad Sci USA. 2015;112:E6736\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5243_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nbt.3439","volume":"34","author":"A Hammond","year":"2016","unstructured":"Hammond A, Galizi R, Kyrou K, Simoni A, Siniscalchi C, Katsanos D, et al. A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector Anopheles gambiae. Nat Biotechnol. 2016;34:78\u201383.","journal-title":"Nat Biotechnol"},{"key":"5243_CR14","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1534\/g3.120.401133","volume":"10","author":"VM Macias","year":"2020","unstructured":"Macias VM, McKeand S, ChaverraRodriguez D, Hughes GL, Fazekas A, Pujhari S, et al. Cas9-mediated gene-editing in the malaria mosquito Anopheles stephensi by ReMOT Control. G3 Bethesda. 2020;10:1353\u201360.","journal-title":"G3 Bethesda."},{"key":"5243_CR15","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.2147\/IDR.S405668","volume":"16","author":"M Fikadu","year":"2023","unstructured":"Fikadu M, Ashenafi E. Malaria: an overview. Infect Drug Resist. 2023;16:3339\u201347.","journal-title":"Infect Drug Resist"},{"key":"5243_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1146\/annurev-pathmechdis-012419-032640","volume":"15","author":"CA Moxon","year":"2020","unstructured":"Moxon CA, Gibbins MP, McGuinness D, Milner DA Jr, Marti M. New insights into malaria pathogenesis. Annu Rev Pathol. 2020;15:315\u201343.","journal-title":"Annu Rev Pathol"},{"key":"5243_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/14760584.2021.1874923","volume":"20","author":"RJ Nevagi","year":"2021","unstructured":"Nevagi RJ, Good MF, Stanisic DI. Plasmodium infection and drug cure for malaria vaccine development. Expert Rev Vaccines. 2021;20:163\u201383.","journal-title":"Expert Rev Vaccines"},{"key":"5243_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/14760584.2021.1882309","volume":"20","author":"DI Stanisic","year":"2021","unstructured":"Stanisic DI, McCall MB. Correlates of malaria vaccine efficacy. Expert Rev Vaccines. 2021;20:143\u201361.","journal-title":"Expert Rev Vaccines"},{"key":"5243_CR19","volume-title":"Malaria vaccines: preferred product characteristics and clinical development considerations","author":"WHO","year":"2022","unstructured":"WHO. Malaria vaccines: preferred product characteristics and clinical development considerations. Geneva: World Health Organization; 2022."},{"key":"5243_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41541-020-0196-3","volume":"5","author":"PE Duffy","year":"2020","unstructured":"Duffy PE, Patrick GJ. Malaria vaccines since 2000: progress, priorities, products. NPJ Vaccines. 2020;5:48.","journal-title":"NPJ Vaccines"},{"issue":"11","key":"5243_CR21","volume":"2014","author":"RTS, S Clinical Trials Partnership","year":"2014","unstructured":"RTS, S Clinical Trials Partnership. Efficacy and safety of the RTS, S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;2014(11): e1001685.","journal-title":"PLoS Med"},{"key":"5243_CR22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40259-023-00623-4","volume":"37","author":"DI Stanisic","year":"2023","unstructured":"Stanisic DI, Good MF. Malaria vaccines: progress to date. BioDrugs. 2023;37:737\u201356.","journal-title":"BioDrugs"},{"key":"5243_CR23","doi-asserted-by":"publisher","first-page":"2376945","DOI":"10.1080\/27707571.2024.2376945","volume":"11","author":"Z Makuvara","year":"2024","unstructured":"Makuvara Z, Magano SR, Mugumbate G. Malaria situation and elimination in Africa with specific focus on Zimbabwe: a systematic review. Cogent Public Health. 2024;11:2376945.","journal-title":"Cogent Public Health"},{"key":"5243_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2147\/CEOR.S299050","volume":"13","author":"Y Wagnew","year":"2021","unstructured":"Wagnew Y, Hagos T, Weldegerima B, Debie A. Willingness to pay for childhood malaria vaccine among caregivers of under-five children in Northwest Ethiopia. Clinicoecon Outcomes Res. 2021;13:165\u201374.","journal-title":"Clinicoecon Outcomes Res"},{"key":"5243_CR25","doi-asserted-by":"publisher","first-page":"2302504","DOI":"10.1080\/07853890.2024.2302504","volume":"55","author":"YA Tajudeen","year":"2023","unstructured":"Tajudeen YA, Oladipo HJ, Oladunjoye IO, Oladipo MK, Shittu HD, Abdulmumeen IF, et al. Transforming malaria prevention and control: the prospects and challenges of gene drive technology for mosquito management. Ann Med. 2023;55:2302504.","journal-title":"Ann Med"},{"key":"5243_CR26","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1080\/13102818.2021.1996269","volume":"35","author":"R Mudziwapasi","year":"2021","unstructured":"Mudziwapasi R, Changara MC, Ndudzo A, Kaseke T, Godobo F, Mtemeli FL, et al. Gene drives in malaria control: what we need to know. Biotechnol Biotechnol Equip. 2021;35:1623\u201331.","journal-title":"Biotechnol Biotechnol Equip"},{"key":"5243_CR27","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1038\/s41467-021-24790-6","volume":"12","author":"A Hammond","year":"2021","unstructured":"Hammond A, Pollegioni P, Persampieri T, North A, Minuz R, Trusso A, et al. Gene-drive suppression of mosquito populations in large cages as a bridge between lab and field. Nat Commun. 2021;12:4589.","journal-title":"Nat Commun"},{"key":"5243_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202000282","volume":"43","author":"GC Lanzaro","year":"2021","unstructured":"Lanzaro GC, S\u00e1nchez C, Collier TC, Marshall JM, James AA. Population modification strategies for malaria vector control are uniquely resilient to observed levels of gene drive resistance alleles. BioEssays. 2021;43: e2000282.","journal-title":"BioEssays"},{"key":"5243_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007039","volume":"13","author":"AM Hammond","year":"2017","unstructured":"Hammond AM, Kyrou K, Bruttini M, North A, Galizi R, Karlsson X, et al. The creation and selection of mutations resistant to a gene drive over multiple generations in the malaria mosquito. PLoS Genet. 2017;13: e1007039.","journal-title":"PLoS Genet"},{"key":"5243_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12936-024-05160-1","volume":"23","author":"N Sykes","year":"2024","unstructured":"Sykes N, Bigirwenkya J, Coche I, Drabo M, Dzokoto D, O\u2019Loughlin S, et al. Procedural legitimacy: co-developing a community agreement model for genetic approaches research to malaria control in Africa. Malar J. 2024;23:359.","journal-title":"Malar J"},{"key":"5243_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12936-022-04241-3","volume":"21","author":"L Pare Toe","year":"2022","unstructured":"Pare Toe L, Dicko B, Linga R, Barry N, Drabo M, Sykes N, et al. Operationalizing stakeholder engagement for gene drive research in malaria elimination in Africa\u2014translating guidance into practice. Malar J. 2022;21:225.","journal-title":"Malar J"},{"key":"5243_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4269\/ajtmh.23-0862","volume":"111","author":"A Kormos","year":"2024","unstructured":"Kormos A, Nazar\u00e9 L, dos Santos AA, Lanzaro GC. Practical application of a relationship-based model to engagement for gene-drive vector control programs. Am J Trop Med Hyg. 2024;111:341\u201360.","journal-title":"Am J Trop Med Hyg"},{"key":"5243_CR33","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41579-024-01065-7","volume":"22","author":"PE Duffy","year":"2024","unstructured":"Duffy PE, Gorres JP, Healy SA, Fried M. Malaria vaccines: a new era of prevention and control. Nat Rev Microbiol. 2024;22:756\u201372.","journal-title":"Nat Rev Microbiol"},{"key":"5243_CR34","doi-asserted-by":"publisher","first-page":"1940639","DOI":"10.1080\/2331205X.2021.1940639","volume":"8","author":"AB Orok","year":"2021","unstructured":"Orok AB, Ajibaye O, Aina OO, Iboma G, Adagyo Oboshi S, Iwalokun B. Malaria interventions and control programmes in sub-Saharan Africa: a narrative review. Cogent Med. 2021;8:1940639.","journal-title":"Cogent Med"},{"key":"5243_CR35","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2147\/RMHP.S219294","volume":"14","author":"N Arora","year":"2021","unstructured":"Arora N, Anbalagan CL, Pannu AK. Towards eradication of malaria: is the WHO\u2019s RTS, S\/AS01 vaccination effective enough? Risk Manag Healthc Policy. 2021;14:1033\u20139.","journal-title":"Risk Manag Healthc Policy."},{"key":"5243_CR36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/20477724.2018.1438880","volume":"111","author":"AM Hammond","year":"2017","unstructured":"Hammond AM, Galizi R. Gene drives to fight malaria: current state and future directions. Pathog Glob Health. 2017;111:412\u201323.","journal-title":"Pathog Glob Health"},{"key":"5243_CR37","doi-asserted-by":"crossref","unstructured":"Bottino-Rojas V, James AA. Population modification using gene drive for reduction of malaria transmission. In: Benedict, Scott MJ (eds). Transgenic insects: techniques and applications. Chapt 11. CABI Publ. 2022","DOI":"10.1079\/9781800621176.0011"},{"key":"5243_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/bs.apar.2016.09.004","volume":"97","author":"RE Sinden","year":"2017","unstructured":"Sinden RE. Targeting the parasite to suppress malaria transmission. Adv Parasitol. 2017;97:147\u201385.","journal-title":"Adv Parasitol"},{"issue":"Suppl 6","key":"5243_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4269\/ajtmh.18-0083","volume":"98","author":"S James","year":"2018","unstructured":"James S, Collins FH, Welkhoff PA, Emerson C, Godfray HC, Gottlieb M, et al. Pathway to deployment of gene drive mosquitoes as a potential biocontrol tool for elimination of malaria in sub-Saharan Africa: recommendations of a scientific working group. Am J Trop Med Hyg. 2018;98(Suppl 6):1\u201349.","journal-title":"Am J Trop Med Hyg"},{"key":"5243_CR40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/joim.12223","volume":"275","author":"C Arama","year":"2014","unstructured":"Arama C, Troye-Blomberg M. The path of malaria vaccine development: challenges and perspectives. J Intern Med. 2014;275:456\u201366.","journal-title":"J Intern Med"},{"key":"5243_CR41","doi-asserted-by":"publisher","first-page":"8976","DOI":"10.1038\/s41467-024-53065-z","volume":"15","author":"PA Hancock","year":"2024","unstructured":"Hancock PA, North A, Leach AW, Winskill P, Ghani AC, Godfray HCJ, et al. The potential of gene drives in malaria vector species to control malaria in African environments. Nat Commun. 2024;15:8976.","journal-title":"Nat Commun"},{"key":"5243_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12936-019-2978-5","volume":"18","author":"JL Teem","year":"2019","unstructured":"Teem JL, Ambali A, Glover B, Ouedraogo J, Makinde D, Roberts A. Problem formulation for gene drive mosquitoes designed to reduce malaria transmission in Africa: results from four regional consultations 2016\u20132018. Malar J. 2019;18:347.","journal-title":"Malar J"},{"key":"5243_CR43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12936-021-03674-6","volume":"20","author":"JB Connolly","year":"2021","unstructured":"Connolly JB, Mumford JD, Fuchs S, Turner G, Beech C, North AR, et al. Systematic identification of plausible pathways to potential harm via problem formulation for investigational releases of a population suppression gene drive to control the human malaria vector Anopheles gambiae in West Africa. Malar J. 2021;20:170.","journal-title":"Malar J"},{"key":"5243_CR44","doi-asserted-by":"publisher","first-page":"1261123","DOI":"10.3389\/fbioe.2023.1261123","volume":"11","author":"A Kormos","year":"2023","unstructured":"Kormos A, Dimopoulos G, Bier E, Lanzaro GC, Marshall JM, James AA. Conceptual risk assessment of mosquito population modification gene-drive systems to control malaria transmission: preliminary hazards list workshops. Front Bioeng Biotechnol. 2023;11:1261123.","journal-title":"Front Bioeng Biotechnol"},{"key":"5243_CR45","unstructured":"World Economic Forum. Here\u2019s how reducing malaria can add $16 billion to Africa\u2019s GDP every year. 2024. https:\/\/www.weforum.org\/stories\/2024\/06\/malaria-global-health-economy-africa\/. (Accessed 19 Dec 2024)"},{"key":"5243_CR46","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12936-023-04787-w","volume":"22","author":"MF Finda","year":"2023","unstructured":"Finda MF, Juma EO, Kahamba NF, Mthawanij RS, Sambo M, Emidi B, et al. Perspectives of African stakeholders on gene drives for malaria control and elimination: a multi-country survey. Malar J. 2023;22:384.","journal-title":"Malar J"},{"key":"5243_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11248-023-00335-z","volume":"32","author":"SL James","year":"2023","unstructured":"James SL, Dass B, Quemada H. Regulatory and policy considerations for the implementation of gene drive-modified mosquitoes to prevent malaria transmission. Transgenic Res. 2023;32:17\u201332.","journal-title":"Transgenic Res"},{"key":"5243_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12762","volume":"42","author":"RM Nateghi","year":"2020","unstructured":"Nateghi RM. CRISPR\/Cas9 gene drive technology to control transmission of vector-borne parasitic infections. Parasite Immunol. 2020;42: e12762.","journal-title":"Parasite Immunol"},{"key":"5243_CR49","doi-asserted-by":"publisher","first-page":"22805","DOI":"10.1073\/pnas.2010214117","volume":"117","author":"R Carballar-Lejaraz\u00fa","year":"2020","unstructured":"Carballar-Lejaraz\u00fa R, Ogaugwu C, Tushar T, Kelsey A, Pham TB, Murphy J, et al. Next-generation gene drive for population modification of the malaria vector mosquito, Anopheles gambiae. Proc Natl Acad Sci USA. 2020;117:22805\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5243_CR50","first-page":"445","volume":"3","author":"J Cha","year":"2001","unstructured":"Cha J, Ranweiler JS, Lane PA. Stability studies. Separation. Sci Technol. 2001;3:445\u201383.","journal-title":"Sci Technol"},{"key":"5243_CR51","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/vbz.2019.2606","volume":"20","author":"SL James","year":"2020","unstructured":"James SL, Marshall JM, Christophides GK, Okumu FO, Nolan T. Toward the definition of efficacy and safety criteria for advancing gene drive-modified mosquitoes to field testing. Vector-Borne Zoonotic Dis. 2020;20:237\u201351.","journal-title":"Vector-Borne Zoonotic Dis"},{"key":"5243_CR52","unstructured":"Subsidiary Body on Scientific, Technical and Technological Advice. Additional voluntary guidance materials to support case-by-case risk assessments of living modified organisms containing engineered gene drives. Twenty-sixth meeting; 2024. Nairobi."},{"key":"5243_CR53","unstructured":"Conference of the parties to the convention on biological diversity serving as the meeting of the parties to the cartagena protocol on biosafety. review of effectiveness of processes under the convention and its protocols. Eleventh meeting; 2024 Nov 1; Cali, Colombia"},{"key":"5243_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejphar.2015.02.055","volume":"759","author":"PJ Van Meer","year":"2015","unstructured":"Van Meer PJ, Graham ML, Schuurman HJ. The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals. Eur J Pharmacol. 2015;759:3\u201313.","journal-title":"Eur J Pharmacol"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05243-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05243-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05243-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T22:36:02Z","timestamp":1737153362000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05243-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5243"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05243-7","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"23 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}